Top

Published in:

01-10-2004 | Diagnostic Neuroradiology

Substantia innominata: MR findings in Parkinson’s disease

Authors: Hirobumi Oikawa, Makoto Sasaki, Shigeru Ehara, Takashi Abe

Published in: Neuroradiology | Issue 10/2004

Abstract

To elucidate MR imaging changes of the substantia innominata in Parkinson’s disease (PD), using a 1.5-T superconductive MR unit, the thickness of the substantia innominata was measured on coronal thin-section images in 44 PD patients and 20 age-matched control subjects. We also evaluated the correlation between the thickness of the substantia innominata and mental status in PD patients. Mean thickness of the substantia innominata was 2.3 mm in PD patients, and 2.5 mm in control subjects. Thinning of the substantia innominata was statistically significant in PD patients compared with control subjects, although there were large overlaps. Among the PD patients, thinning was remarkable in cases with dementia. A positive correlation between thickness of substantia innominata and score of Mini-Mental-Status-Examination was also observed in PD patients. Atrophy of the substantia innominata was demonstrated, especially in PD patients with cognitive impairment, on coronal MR images, and this is compatible with the previous pathological reports.

Whitehouse PJ, Hedreen JC, White CL 3rd, Price DL (1983) Basal forebrain neurons in the dementia of Parkinson’s disease. Ann Neurol 13:243–248PubMed

Sasaki M, Ehara S, Tamakawa Y et al (1995) MR anatomy of the substantia innominata and findings in Alzheimer disease; A preliminary report. Am J Neuroradiol 16:2001–2007PubMed

Hanyu H, Tanaka Y, Sakurai H, Takasaki M, Abe K (2002) Atrophy of the substantia innominata on magnetic resonance imaging and response to donepezil treatment in Alzheimer’s disease. Neurosci Lett 319:33–36CrossRefPubMed

Hanyu H, Asano T, Sakurai H et al (2002) MR analysis of the substantia innominata in normal aging, Alzheimer disease, and other types of dementia. Am J Neuroradiol 23:27–32PubMed

Calne DB, Snow BJ, Lee C (1992) Criteria for diagnosing Parkinson’s disease. Ann Neurol 32:S125–127PubMed

Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR (1981) Alzheimer’s disease; evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 10:122–126PubMed

Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, DeLong MR (1982) Alzheimer’s disease and senile dementia: loss of neurons in the basal forebrain. Science 215:1234–1237

Rossor MN, Garrett NJ, Johnson AL, Mountjoy CQ, Roth M, Iversen LL (1982) A post-mortem study of the cholinergic and GABA systems in senile dementia. Brain 105:313–330PubMed

White P, Hiley CR, Goodhardt MJ et al (1977) Neocortical cholinergic neurons in elderly people. Lancet I:668–671CrossRef

10.

Davies P, Maloney AJF (1976) Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet II: 1403CrossRef

11.

Whitehouse PJ (1986) Clinical and neurochemical consequences of neuronal loss in the nucleus basalis of Meynert in Parkinson’s disease and Alzheimer’s disease. Adv Neurol 45:393–397

12.

Loranger AW, Goodell H, McDowell FH et al (1972) Intellectual impairment in Parkinson’s syndrome. Brain 95:405–412PubMed

13.

Morris JC, Drazner M, Fulling K, Grant EA, Goldring J (1989) Clinical and pathological aspects of parkinsonism in Alzheimer’s disease: a role for extranigral factors? Arch Neurol 46:651–657PubMed

14.

Bruno D, Merle R, France JA, Alain P, Yves A (1983) A subcortico-cortical cholinergic system is affected in Parkinson’s disease. Brain Res 288:213–218CrossRefPubMed

15.

Hirano A, Zimmerman HM (1962) Alzheimer’s neurofibrillary changes. Arch Neurol 7:227–242PubMed

16.

Steven JH, Edwin CS, Jeffrey AC, Donald WC, Andrew C, George WP (1989) Magnetic resonance imaging in dementia of Parkinson’s disease. J Neurol Neurosurg Psychiatry 52:1221–1227PubMed

17.

Lichter DG, Corbett AJ, Fitzgibbon GM et al (1988) Cognitive and motor dysfunction in Parkinson’s disease. Clinical, performance and computed tomographic correlations. Arch Neurol 45:854–860PubMed

18.

Hanyu H, Asano T, Sakurai H, Takasaki M, Shindo H, Abe K (2001) Magnetization transfer measurement of the subcortical gray and white matter in Parkinson’s disease with and without dementia and in progressive supranuclear palsy. Neuroradiology 43:542–546CrossRefPubMed

19.

Carpenter MB, Sutin J (1991) Human neuroanatomy, 4th edn. Williams and Wilkins, Baltimore, pp 382–384

20.

Mesulam MM, Mufson EJ, Levey AI et al (1983) Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. J Comp Neurol 214:170–197PubMed

21.

Mesulam MM, Van Hoesen GW (1976) Acetylcholinesterase-rich projections from the basal forebrain of the rhesus monkey to neocortex. Brain Res 109:152–157CrossRefPubMed

Title: Substantia innominata: MR findings in Parkinson’s disease
Authors: Hirobumi Oikawa
Makoto Sasaki
Shigeru Ehara
Takashi Abe
Publication date: 01-10-2004
Publisher: Springer-Verlag
Published in: Neuroradiology / Issue 10/2004
Print ISSN: 0028-3940
Electronic ISSN: 1432-1920
DOI: https://doi.org/10.1007/s00234-004-1257-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Substantia innominata: MR findings in Parkinson’s disease

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2004

Reversible encephalopathy syndrome: report of 12 cases with follow-up

Diffusion MR findings in cyclosporin-A induced encephalopathy

Cerebellar pleomorphic xanthoastrocytoma in a patient with neurofibromatosis type 1

Glucocorticoid treatment of brain tumor patients: changes of apparent diffusion coefficient values measured by MR diffusion imaging

CT findings of bilateral congenital absence of the long process of the incus

Magnetic resonance imaging findings in Kimura’s disease